ERBB2 and breast cancer: Mechanistic investigations suggest that melittin suppresses breast cancer progression by inhibiting growth factor receptor activation (e.g., HER2) and inducing apoptosis through caspase activation and modulation of the Bax/Bcl-2 pathways [11,74].